SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Nifty Healthcare Index Companies

BSE Sensex 76664.21
999.79 (-1.29%)

See MoneyWorks4me's rating on Quality, Valuation, Price Trend and Overall Rating to take informed stock investing decisions. Decizen :- Q: Quality, V: Valuation, PT: Price Trend

Filter

Nifty Healthcare Index companies as on Apr-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	CMP	Price Change (%)	Market Cap (Cr)	52Week High	52Week Low	ROE(%)	P/E	P/BV	EV/ EBITDA	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Ipca Laboratories Ltd	Q V+ PT	1,558	2.31%	39,531 Mid Cap	1,624 17 Mar, 26	1,253 24 Oct, 25	12.48	49.10	5.13	22.37	8.87	4.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Piramal Pharma Ltd	Q V PT	165	1.01%	21,992 Small Cap	226 15 May, 25	133 23 Mar, 26	9.79	30.73	2.79	17.76	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Fortis Healthcare Ltd	Q V+ PT	928	0.15%	70,068 Mid Cap	1,105 13 Oct, 25	623 09 May, 25	1.59	429.49	7.61	135.40	15.55	-22.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Divis Laboratories Ltd	Q V PT	6,359	-0.31%	1,68,817 Large Cap	7,078 08 Jul, 25	5,638 29 Sep, 25	15.14	68.10	10.55	43.24	11.65	10.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Apollo Hospitals Enterprise Ltd	Q V+ PT	7,726	-0.59%	1,11,083 Large Cap	8,099 23 Oct, 25	6,680 28 Jan, 26	15.77	76.94	11.45	42.78	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Torrent Pharmaceuticals Ltd	Q V+ PT	4,116	-0.72%	1,39,297 Large Cap	4,480 13 Mar, 26	3,101 09 May, 25	26.68	61.31	15.33	34.67	7.72	15.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Max Healthcare Institute Ltd	Q V PT	999	-0.76%	97,256 Mid Cap	1,314 04 Jul, 25	904 07 Apr, 26	12.68	68.53	9.39	43.07	46.01	60.18	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Cipla Ltd	Q V PT	1,295	-0.85%	1,04,588 Large Cap	1,672 23 Oct, 25	1,166 02 Apr, 26	17.79	23.00	3.11	13.87	9.97	30.14	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Abbott India Ltd	Q V PT	25,198	-0.88%	53,545 Mid Cap	35,922 03 Jul, 25	25,167 24 Apr, 26	35.71	35.13	12.21	24.56	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Mankind Pharma Ltd	Q V PT	2,267	-1.09%	93,582 Mid Cap	2,727 15 Jul, 25	1,910 23 Mar, 26	14.52	54.93	5.86	33.07	14.65	12.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Dr. Reddys Laboratories Ltd	Q V PT	1,316	-1.29%	1,09,828 Mid Cap	1,378 12 Jun, 25	1,121 07 May, 25	17.66	19.72	2.95	11.85	13.26	22.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Laurus Labs Ltd	Q V+ PT	1,114	-1.36%	60,113 Mid Cap	1,145 20 Apr, 26	573 09 May, 25	7.37	71.28	11.88	34.79	14.42	4.11	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Aurobindo Pharma Ltd	Q V+ PT	1,414	-1.54%	82,114 Mid Cap	1,460 23 Apr, 26	1,017 02 Sep, 25	8.24	38.54	3.73	25.42	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Syngene International Ltd	Q V+ PT	421	-1.67%	16,972 Small Cap	728 30 Jul, 25	380 06 Apr, 26	9.91	51.26	3.66	18.39	10.89	4.48	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Glenmark Pharmaceuticals Ltd	Q V+ PT	2,298	-1.68%	64,851 Mid Cap	2,372 24 Apr, 26	1,340 05 May, 25	15.43	60.89	6.49	13.55	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Lupin Ltd	Q V PT	2,296	-1.88%	1,04,973 Mid Cap	2,381 23 Apr, 26	1,839 06 Aug, 25	20.83	22.60	5.04	13.48	8.11	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Zydus Lifesciences Ltd	Q V PT	927	-2.11%	93,293 Mid Cap	1,059 19 Sep, 25	836 02 Apr, 26	20.74	18.89	3.55	11.77	10.27	30.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Biocon Ltd	Q V PT	350	-2.28%	56,675 Mid Cap	425 18 Nov, 25	309 25 Apr, 25	1.61	7658.79	2.10	106.26	2.44	-9.71	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Sun Pharmaceutical Industries Ltd	Q V PT	1,620	-3.57%	3,88,680 Large Cap	1,851 02 May, 25	1,547 26 Sep, 25	16.60	35.61	4.79	19.43	9.87	23.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Alkem Laboratories Ltd	Q V PT	5,229	-5.22%	62,518 Mid Cap	5,933 13 Jan, 26	4,717 10 Jul, 25	17.86	28.50	4.38	21.88	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Nifty Healthcare Index - Today's Top Gainers

Company Name	CMP	Price Change(%)
Ipca Laboratories	1,558.15	2.31%
Piramal Pharma	165.45	1.01%
Fortis Healthcare	928.10	0.15%

Nifty Healthcare Index - Today's Top Losers

Company Name	CMP	Price Change(%)
Alkem Laboratories	5,228.75	-5.22%
Sun Pharma Inds.	1,619.95	-3.57%
Biocon	349.65	-2.28%
Zydus Lifesciences	927.15	-2.11%
Lupin	2,296.10	-1.88%

News about Nifty Healthcare Index

Apr, 2026

Dr. Reddy’s Laboratories informs about clarification on news item

With reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) regarding a news item appearing in ‘https://www.cnbctv18.com/’dated April 23, 2026 captioned ‘Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say’. In this connection, Dr. Reddy’s Laboratories has informed that the above captioned news item headline is correct, as the Company has not yet received approval (‘Notice of Compliance’) for its Semaglutide Injection from Health Canada. Further it has informed that as part of the regulatory review process, the Company has received the ‘Drug Identification Numbers (DINs)’ for Semaglutide Injection from Health Canada on April 22, 2026. The company continue to engage constructively with the regulatory authority and remain committed to bringing the product to the Canadian market upon approval. In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations. The company has informed that at this stage there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Cipla shines as its arm gets USFDA’s final nod for Albuterol Sulfate Inhalation Aerosol

This approval enhances Cipla’s U.S. respiratory portfolio and reinforces its leadership in the Albuterol inhalation category

Apr, 2026

Cipla’s arm gets USFDA’s final nod for Albuterol Sulfate Inhalation Aerosol

This approval enhances Cipla’s U.S. respiratory portfolio and reinforces its leadership in the Albuterol inhalation category

Apr, 2026

Cipla informs about disclosure

Pursuant to the provisions of Regulation 30 read with Schedule III Part A Para B of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the SEBI circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026, Cipla has informed that the Cipla USA Inc., wholly owned subsidiary of the Company in USA (referred as ‘Cipla’) has received final approval from the United States Food and Drug Administration (‘USFDA’) for the Abbreviated New Drug Application (‘ANDA’) submitted for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation, the first AB rated generic therapeutic equivalent of Ventolin® HFA, marketed by GlaxoSmithKline. Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise induced bronchospasm in patients aged four years and older. The product is expected to be launched in H1 of FY 2026-27 in the United States of America. A press release dated 23rd April 2026 is also enclosed.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Zydus Lifesciences informs about newspaper publication

Zydus Lifesciences has informed that it enclosed the Newspaper Publication of Notice for opening of Special Window for transfer and dematerialization of physical securities, published in the Financial Express English and Gujarati Editions, both on April 22, 2026.

The above information is a part of company’s filings submitted to BSE.

Apr, 2026

Abbott India informs about change in management

Abbott India has informed about following outcome of the Board Meeting held today i.e., April 22, 2026. Anisha Motwani (DIN: 06943493), Independent Director, will be completing her second term as an Independent Director of the Company on April 24, 2026. Accordingly, she ceases to be the Director of the Company with effect from the close of business hours on April 24, 2026. Details pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 (SEBI Circular), is enclosed as Annexure; Appointment of Neeraj Jain (DIN: 00348591) as an Additional Director designated as an Independent Director, with effect from April 25, 2026; etc.

The above information is a part of company’s filings submitted to BSE.

Track Now:

5 Star Companies Large Cap Companies Mid Cap Companies Small Cap Companies Nifty Microcap Companies Top IT Companies Tax saver funds Analyze your Equity Funds Nifty Index Funds

All Indices

Broad Based Indices:

Nifty 50 Nifty Next 50 Nifty 100 Nifty 200 Nifty Total Market Nifty 500 Nifty Midcap 150 Nifty Midcap 50 Nifty Midcap Select Nifty Midcap 100 Nifty Smallcap 250 Nifty Smallcap 50 NIFTY Smallcap 100 Nifty Microcap 250 Nifty Largemidcap 250 Nifty500 Multicap 50:25:25

Sectoral Indices:

Nifty Auto Nifty Bank Nifty Healthcare Nifty IT Nifty Financial Services Nifty Media Nifty Metal Nifty Pharma Nifty Private Bank Nifty PSU Bank Nifty Realty Nifty Consumer Durables Nifty Oil & Gas Nifty Financial Services 25/50 Nifty Financial Services Ex Bank Nifty FMCG

Thematic Indices:

Nifty Aditya Birla Group Nifty Core Housing Nifty Commodities Nifty CPSE Nifty Financial Services Nifty Energy Nifty Housing Nifty India Consumption Nifty India Defence Nifty India Digital Nifty India Manufacturing Nifty Infrastructure Nifty Mahindra Group Nifty Midcap Liquid 15 Nifty MNC Nifty Mobility Nifty PSE Nifty Non-cyclical Consumer Nifty Services Sector Nifty Shariah 25 Nifty Tata Group Nifty Tata Group 25% Cap Nifty Transportation & Logistics Nifty100 Liquid 15 Nifty50 Shariah Nifty500 Shariah NIFTY SME EMERGE Nifty100 Esg NIFTY100 Enhanced ESG Nifty100 ESG Sector Leaders

Strategy Indices:

Nifty100 Equal Weight Nifty100 Low Volatility 30 Nifty 50 Arbitrage Nifty200 Momentum 30 NIFTY100 Alpha 30 Nifty Alpha 50 Nifty Alpha Low-volatility 30 Nifty Alpha Quality Low-volatility 30 Nifty Alpha Quality Value Low-volatility 30 Nifty Growth Sectors 15 Nifty High Beta 50 NIFTY100 Quality 30 NIFTY Midcap150 Quality 50 Nifty Quality Low Volatility 30 Nifty50 Dividend Points Nifty50 Equal Weight Nifty50 Value 20 Nifty500 Value 50 Nifty200 Quality 30

Nifty Healthcare Index FAQs

You can use different criterias to arrive at the list of best stocks in the Nifty Healthcare Index company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Healthcare Index companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,198	53,545	35.13	12.21	24.56	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,116	1,39,297	61.31	15.33	34.67	26.68
Lupin Ltd. (M)	Somewhat Good	2,296	1,04,973	22.60	5.04	13.48	20.83
Zydus Lifesciences Ltd. (M)	Very Good	927	93,293	18.89	3.55	11.77	20.74
Alkem Laboratories Ltd. (M)	Very Good	5,229	62,518	28.50	4.38	21.88	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,114	60,113	72.06
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,298	64,851	61.62
Fortis Healthcare Ltd. (M)	Not Good	928	70,068	38.87
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,116	1,39,297	23.81
Aurobindo Pharma Ltd. (M)	Very Good	1,414	82,114	12.42
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Max Healthcare Institute Ltd. (M)	N/A	999	97,256	68.53	9.39	43.07	46.01
Fortis Healthcare Ltd. (M)	Not Good	928	70,068	429	7.61	135	15.55
Mankind Pharma Ltd. (M)	Very Good	2,267	93,582	54.93	5.86	33.07	14.65
Laurus Labs Ltd. (M)	Very Good	1,114	60,113	71.28	11.88	34.79	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,316	1,09,828	19.72	2.95	11.85	13.26

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Max Healthcare Institute Ltd. (M)	N/A	999	97,256	68.53	9.39	43.07	60.18
Zydus Lifesciences Ltd. (M)	Very Good	927	93,293	18.89	3.55	11.77	30.57
Cipla Ltd. (L)	Very Good	1,295	1,04,588	23.00	3.11	13.87	30.14
Apollo Hospitals Enterprise Ltd. (L)	Somewhat Good	7,726	1,11,083	76.94	11.45	42.78	29.94
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,620	3,88,680	35.61	4.79	19.43	23.50

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Nifty Healthcare Index Companies

News about Nifty Healthcare Index

Dr. Reddy’s Laboratories informs about clarification on news item

Cipla shines as its arm gets USFDA’s final nod for Albuterol Sulfate Inhalation Aerosol

Cipla’s arm gets USFDA’s final nod for Albuterol Sulfate Inhalation Aerosol

Cipla informs about disclosure

Zydus Lifesciences informs about newspaper publication

Abbott India informs about change in management